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Abstract
The peripheral naı ¨ve T cell pool is comprised of a heterogeneous population of cells at various stages of development,
which is a process that begins in the thymus and is completed after a post-thymic maturation phase in the periphery. One
hallmark of naı ¨ve T cells in secondary lymphoid organs is their unique ability to produce TNF rapidly after activation and
prior to acquiring other effector functions. To determine how maturation influences the licensing of naı ¨ve T cells to produce
TNF, we compared cytokine profiles of CD4
+ and CD8
+ single positive (SP) thymocytes, recent thymic emigrants (RTEs) and
mature-naı ¨ve (MN) T cells during TCR activation. SP thymocytes exhibited a poor ability to produce TNF when compared to
splenic T cells despite expressing similar TCR levels and possessing comparable activation kinetics (upregulation of CD25
and CD69). Provision of optimal antigen presenting cells from the spleen did not fully enable SP thymocytes to produce
TNF, suggesting an intrinsic defect in their ability to produce TNF efficiently. Using a thymocyte adoptive transfer model, we
demonstrate that the ability of T cells to produce TNF increases progressively with time in the periphery as a function of
their maturation state. RTEs that were identified in NG-BAC transgenic mice by the expression of GFP showed a significantly
enhanced ability to express TNF relative to SP thymocytes but not to the extent of fully MN T cells. Together, these findings
suggest that TNF expression by naı ¨ve T cells is regulated via a gradual licensing process that requires functional maturation
in peripheral lymphoid organs.
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Introduction
T cell development begins within the thymus and is driven to
completion after single positive (SP) thymocytes exit the thymus
and seed secondary lymphoid organs, where they undergo
progressive phenotypic and functional maturation [1]. The
peripheral naı ¨ve T cell pool is therefore comprised of a
heterogeneous population of cells at different stages of post-thymic
development, encompassing T cell subsets from the fully mature to
the most recently emigrated thymic T cells [2]. The recent thymic
emigrants (RTEs), which are 0–2 weeks old in the periphery have
a distinct phenotypic profile (CD24
high, Qa2
low, CD45RB
low)
relative to their mature naı ¨ve (MN) counterparts, that are resident
in the periphery for .3 weeks (CD24
low, Qa2
high, CD45RB
high)
[1,3]. RTEs have been shown to also differ functionally, producing
less IL-2, exhibiting a decreased ability to proliferate upon
48 hours of in vitro TCR stimulation and producing less IFN-c
after 7 days of infection with ovalbumin-expressing Listeria
monocytogenes (rLM-OVA) [1,3]. Resting naı ¨ve T cells in secondary
lymphoid organs are quiescent in nature requiring a low level of
TCR signaling from self peptide-MHC ligands to maintain
immune homeostasis [4]. Upon antigen-specific activation, naı ¨ve
T cells differentiate and clonally expand to become effectors that
are capable of secreting cytokines (IL-2, TNF and IFN-c) and
exhibiting cytolytic function [5,6,7]. In contrast to this conven-
tional paradigm, naı ¨ve CD4
+ and CD8
+ T cells (CD44
lo, CD11a
lo)
have recently been shown to rapidly produce TNF within 4 to
5 hours of TCR engagement, before ensuing cell division or
producing other effector cytokines such as IL-2 or IFN-c [8,9].
The kinetics of TNF production by naı ¨ve T cells suggest that this
potent immunomodulatory cytokine is released during the initial
encounter between T cells and APCs, a critical phase in the
programming of antigen-specific responses [5,10,11,12,13,
14,15,16]. However, when and how naı ¨ve T cells acquire this
unique capability to produce TNF during development is not
known.
TNF is a potent pro-inflammatory cytokine that elicits
pleiotropic effects during an immune response, affecting immune
cell activation, survival, death and differentiation [17,18]. The
effects of TNF are mediated through two distinct receptors,
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TNF signaling pathways has been implicated in the pathogenesis
of several diseases, including rheumatoid arthritis (RA), Crohn’s
disease (CD), inflammatory bowel disease (IBD) and multiple
sclerosis (MS), and hence therapeutic agents that target and block
the activity of TNF have been developed for clinical use
[21,23,24,25,26,27,28]. In addition to being a major inducer of
inflammation during innate immune responses, TNF signaling
also mediates immunomodulatory effects in adaptive immune
responses [29]. For example, TNF signaling plays a vital role in the
generation of functional T cell responses to tumor antigens, DNA
vaccines and recombinant adenoviruses [23,30,31,32]. More
specifically, signaling through TNFR2 but not TNFR1 has a
synergistic role with CD28 co-stimulation, reducing the threshold
of activation for optimal IL-2 expression during the initial stages of
T cell activation [23,33,34,35]. In contrast, there is evidence
suggesting a suppressive role for TNF in the generation of T cell
responses after infection of mice with LCMV. For example, higher
frequencies of LCMV-specific CD4
+ and CD8
+ memory T cells
are detectable in mice with defective TNF signaling pathways
[36,37,38,39]. These studies together indicate that effects of TNF
signaling on the induction of adaptive immune responses are
dependent on the nature of the antigenic challenge.
Given the important role of TNF in regulating immune
responses, here we determined the developmental stage when
naı ¨ve T cells become competent to produce TNF by comparing
the capability of SP naı ¨ve T cells to produce TNF before and after
emigration from the thymus. These studies reveal that CD4
+
CD8
2 and CD4
2 CD8
+ SP thymocytes possess a poor ability to
produce TNF upon stimulation when compared to their
counterparts in secondary lymphoid organs. Contact with
secondary lymphoid cells (spleen and lymph node) during TCR
activation partially enables SP thymocytes to produce TNF in
vitro by providing optimal antigen-presentation. However, the
frequency of TNF producing cells is still significantly lower than in
the periphery. RTEs in the spleen on the other hand, display an
intermediate TNF response, which is higher than their SP thymic
precursors but lower relative to the fully MN T cells. The
differences in the TNF profile exhibited by these 3 populations of
lymphocytes mirrors their distinctive maturation status. Moreover,
as developing T cells mature in the periphery, they show a
progressive increase in their capability to produce TNF upon
TCR activation. Together, these findings suggest that naı ¨ve T cells
become gradually licensed to efficiently produce TNF in a
maturation-dependent manner that requires their localization to
secondary lymphoid organs.
Results
SP thymocytes have an impaired ability to produce TNF
after TCR activation
Naı ¨ve CD4
+ and CD8
+ T lymphocytes (CD44
lo) from
secondary lymphoid organs rapidly produce TNF after TCR
engagement before gaining other effector functions [8]. However,
it is not known at what stage of development naı ¨ve T cells acquire
the ability to produce TNF. To determine this, thymocytes and
splenocytes from CD8
+ and CD4
+ TCR-transgenic mice (P14,
OT-1 & SMARTA and OT-2) were stimulated with specific
peptides and aCD28 costimulation for 4 hrs in vitro. Fig. 1A
shows that a lower proportion of CD4
+ CD8
2 and CD4
2 CD8
+
SP thymocytes produced TNF when compared to naı ¨ve (CD44
lo)
splenic T cells during TCR stimulation. This inability to produce
TNF was not overcome by increasing the concentrations of the
peptide (data not shown). To determine if the reduced TNF
response by SP thymocytes was due to a lower TCR expression on
SP thymocytes relative to naı ¨ve splenic T cells [40,41,42], SP P14-
CD8
+ thymocytes and naı ¨ve (CD44
lo) splenic T cells were stained
with mAbs to TCR Va2 and TCR Vb8.1. Fig. 1B shows that Va2
and Vb8.1 expression in SP P14-CD8
+ thymocytes and splenic T
cells were similar. Next, to determine if the reduced ability of SP
thymocytes to produce TNF was due to a generalized defect in
their activation, we examined the expression of activation markers
CD25, CD69, CD44 and CD62L on the P14-CD8
+ SP
thymocytes and splenic T cells. As shown in Fig. 1C, SP
thymocytes and splenic T cells exhibited a comparable level of
activation at 4 hours, with the expression of CD25 and CD69
being up-regulated and the expression of CD62L down-regulated,
as previously shown [8,43]. These results suggest that SP
thymocytes are incompetent to produce TNF when compared to
splenic T cells upon TCR stimulation despite exhibiting similar
TCR levels and similar phenotypic changes in the expression of
activation markers.
Optimal antigen presentation is not sufficient to enable
thymocytes to produce TNF efficiently
Recent studies have shown that thymic DCs and splenic DCs
have unique properties and that the microenvironment contributes
to their distinct functions [44]. We hypothesized that differences in
TNF production between SP thymocytes and naı ¨ve splenic T cells
may be attributed to the differences in antigen presentation
between the two organs. To test this, enriched CD45.1
+ SP P14-
CD8
+ thymocytes were stimulated in the presence of either WT
CD45.2
+ H-2D
b-positive B6 splenocytes or CD45.2
+ H-2D
b-
deficient B6 splenocytes (incapable of presenting GP33 to P14
cells). In comparison to the high frequencies of TNF-producing
splenocytes depicted in Fig. 1A, there was only a partial increase in
the proportion of SP P14-CD8
+ thymocytes that produced TNF,
when stimulated in the presence of WT B6 splenocytes (Fig. 1D).
Both purified splenic B cells and non-B and -T cell populations
that contained CD11c
+ APCs in the flow-through stimulated this
small increase in TNF production (21.4% and 17.3% of SP P14
CD8
+ thymocytes were TNF positive when stimulated purified B
cells and non-B and -T cell populations, respectively). We then
determined whether SP P14-CD8
+ thymocytes produced TNF as
a consequence of changes occurring in antigen presenting cells
during the co-culture, by using irradiated splenocytes. We found
that SP P14-CD8
+ thymocytes stimulated with irradiated
(3000cGy) WT B6 splenocytes showed a similar increase in the
proportion of TNF producing cells comparable to SP P14-CD8
+
thymocytes stimulated with live WT B6 splenocytes (Fig. 1D),
indicating that viable splenocytes were not necessary for this effect.
As expected, thymocytes stimulated in the presence of H2D
b-
deficient splenocytes (live or irradiated) did not produce TNF.
Together, these results indicate that although optimal TCR-MHC
interactions provided by spleen cells enable a small subset of SP
thymocytes to produce TNF, the frequency of cells and the level of
TNF produced on a per cell basis was reduced compared to
peripheral naı ¨ve CD8
+ splenic T cells, suggesting an intrinsic
defect in SP thymocytes to produce TNF efficiently upon TCR
activation.
Lower level of TNF transcription in SP thymocytes
relative to naı ¨ve splenic T cells during TCR activation
We wanted to determine if the reduced ability of thymocytes to
produce TNF may be related to the levels of mature TNF message
expressed within SP thymocytes. Therefore, we quantified the
steady-state levels of mature TNF mRNA in SP thymocytes
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2CD8
+ and their respective naı ¨ve splenic (CD44
lo) counter-
parts purified from (transgenic) P14 mice at resting state. SP P14-
CD8
+ thymocytes were sorted to 98% purity and (CD44
lo) P14-
CD8
+ splenic T cells were sorted to 90.3% purity Fig. 2A shows
the copy number of TNF transcripts detected in the indicated
groups by quantitative real-time PCR. The levels of mature TNF
message in transgenic SP thymocytes (CD4
2CD8
+) and their
naı ¨ve splenic counterparts were similar and the differences were
not significant (Fig. 2A). Next we compared the levels of TNF
transcripts in purified SP P14-CD8
+ thymocytes and naı ¨ve
(CD44
lo) splenic T cells that were stimulated as indicated. We
found that the levels of TNF mRNA were dramatically higher in
(CD44
lo) P14-CD8
+ splenic T cells during GP33 and
GP33+aCD28 stimulation relative to SP thymocytes. The levels
of TNF transcripts increased in the thymic subsets upon
stimulation but not to the extent detected in the splenic subset
(Fig. 2B). Together, these results indicate that despite having a
basal level of transcription of the TNF gene, SP thymocytes appear
to lack the ability to induce TNF transcription efficiently upon
stimulation relative to naı ¨ve splenic T cells.
Differential ability of SP thymocytes and naı ¨ve splenic T
cells to produce TNF during TCR activation in vivo
To first determine if naı ¨ve splenic T cells produced TNF in the
presence of physiologically relevant levels of antigen, we
performed an in vivo cytokine assay [45]. Briefly, CD45.1
+ P14-
CD8
+ and CD45.1
+ SMARTA-CD4
+ TCR-transgenic splenic T
cells were treated in vitro with bfA, a golgi transport inhibitor that
blocks cytokine secretion. These cells were then mixed and co-
transferred into recipients that were infected with either WT
LCMV-Armstrong or a GP33-CTL escape variant of LCMV
(GP1V) for 2 days. The spleens of recipient mice were recovered
4 hours later and directly stained for intracellular TNF by the
donor T cells. Both P14-CD8
+ and SMARTA-CD4
+ donor T cells
produced TNF in mice that were infected with WT LCMV
Armstrong (Fig. 3A). Only T cells that had down-regulated
CD62L, which is consistent with a TCR-mediated activation
event, were able to produce TNF. In contrast, P14 -CD8
+ donor T
cells in mice that were infected with GP1V mutant virus were
impaired in their ability to produce TNF (Fig. 3A) while
SMARTA-CD4
+ donor T cells were unaffected. These findings
indicate that the in vivo production of TNF by naı ¨ve CD8
+ T cells
during LCMV infection was specifically initiated by TCR-
mediated signaling and was not due to non-specific effects on
naı ¨ve T cells by virus-induced inflammation.
We next examined the ability of SP P14-CD8
+ thymocytes and
SMARTA-CD4
+ thymocytes to produce TNF in the same
scenario. A small but reproducible proportion of both donor SP
P14-CD8
+ and SMARTA-CD4
+ thymocytes produced TNF (4 to
6%TNFpositiveoftotal T cells)during LCMVinfection(Fig.3B).
As expected, infection with GP1V mutant impaired the ability of
the donor SP P14-CD8
+ thymocytes to produce TNF. Fig. 3C
shows the average percentages of TNF producing SP P14-CD8
+
donor thymocytes and splenic T cells that had downregulated
their CD62L expression under the indicated conditions. Togeth-
er, these results confirm our in vitro data indicating that SP
thymocytes are impaired in their ability to produce TNF
efficiently when compared to naı ¨ve splenic T cells during a viral
infection.
TNF producing capability of SP thymocytes correlates
with their maturation state
SP thymocytes are comprised of a heterogeneous population
consisting of cells at different levels of maturity [46]. Immature SP
thymocytes express high levels of CD24 (HSA), which is down-
regulated as cells progress into maturity [47]. This is accompanied
by down-regulation of CD69 and the up-regulation of other
markers such as CD62L, CD45RB and Qa2 [48,49,50]. We first
compared the maturation profile of the total TNF-producing
thymocytes with their TNF non-producing counterparts. We
broadly classified SP P14-CD8
+ thymocytes based on their
maturation status determined by CD24 and Qa2 expression. CD8
SP thymocytes were divided into 4 subgroups from the least mature
to most mature (Fig 4A). Subgroup 1 was comprised of CD24
hi
Qa2
lo cells (least mature) followed by subgroup 2 (CD24
hi-int
Qa2
lo), subgroup 3 (CD24
lo Qa2
lo) and finally subgroup 4
(CD24
lo Qa2
hi) which was the most mature [51]. The small
population of SP P14-CD8
+ thymocytes that produced TNF
displayed a more mature phenotypic profile with the majority of
the TNF producers falling in subgroups 2 and 3 compared to the
TNF non-producers that fell mostly in subgroups 1 and 2. The
maturation differences between the TNF-producing SP thymo-
cytes and the non-producers were also seen in the MFI changes in
CD24, CD45RB and Qa2 (dotted line histograms and gray
histograms in Fig 4C). However, the TNF producing SP P14-
CD8
+ thymocytes had a less mature phenotype when compared
to their splenic counterparts. As described in Fig 4A and Fig 4B,
.60% of the TNF producing thymocytes constituted subgroups
2 and 3 relative to the TNF producing splenic T cells that
constituted .80% in subgroups 3 and 4. The differences were
a l s or e f l e c t e di nt h eM F Io fm a t u r a t i o nm a r k e r s( d a r kl i n e
histograms and black histograms in Fig. 4D). We next examined
the TNF-producing capability of each of the 4 subgroups in the
SP thymic subset individually. The subgroups showed increasing
mean fluorescence intensities of CD45RB, consistent with their
maturation state (Fig 4D). There was a progressive increase in
TNF production on a per cell basis that correlated with
maturation with Subgroup 4 having the highest percentage of
TNF
+ cells. Together, these results suggest that though the small
population of TNF producing SP P14-CD8
+ thymocytes is more
mature than the TNF non-producing counterparts, these cells are
still phenotypically less mature than P14-CD8
+ naı ¨ve T cells
localized in the spleen.
Figure 1. SP thymocytes are poor TNF producers relative to naı ¨ve splenic T cells during TCR activation in vitro. Thymocytes and
splenocytes from P14-CD8
+, OT-1-CD8
+, SMARTA-CD4
+ and OT-2-CD4
+ TCR transgenic mice were stimulated in vitro as indicated for 4 hours and then
stained for intracellular TNF cytokine, as described in Materials and Methods. For analysis, the cells were gated on either SP CD8
+ CD4
2 or SP CD4
+
CD8
2 cells. A, The percentages of TCR transgenic thymocytes and splenic T cells (both CD44
lo and CD44
hi) staining positive for TNF are shown. B,
Resting P14-CD8
+ thymocytes and naı ¨ve splenocytes were stained with mAbs to Va2 and Vb8.1. The profile for the SP thymocytes is shown in gray
solid histograms and for splenic T cells in black line histograms. C, P14-CD8
+ thymocytes and naı ¨ve splenocytes were either unstimulated (gray solid
histograms) or stimulated (black line histograms) for 4 hours with GP33+aCD28 in vitro and stained with mAbs to the indicated surface molecules. D,
CD45.1
+ SP P14-CD8
+ thymocytes were enriched and stimulated with GP33+aCD28 for 4 hours either alone or in the presence of live or irradiated
(3000cGy) H-2D
b WT or H-2D
b KO splenocytes respectively. Cells were then stained for intracellular TNF. The percentages of CD45.1
+ CD8
+
thymocytes (CD44
lo and CD44
hi) staining positive for TNF are shown.
doi:10.1371/journal.pone.0015038.g001
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progressively gain the ability to produce TNF in the
periphery
The differences in TNF production between SP P14-CD8
+
thymocytes and naı ¨ve P14-CD8
+ splenic T cells upon TCR
stimulation parallels the differences in the maturation status of T
cells in these two compartments as shown in Fig 4. The functional
maturation of developing T cells occurs progressively with time
upon contact with secondary lymphoid organs after their exit from
the thymus [1]. Given this, we hypothesized that SP thymocytes
migrating into the periphery will gradually acquire the capability
to produce TNF efficiently upon TCR stimulation. To recapitu-
late thymic emigration, 20610
6 CD45.1
+ P14 thymocytes were
adoptively transferred into uninfected CD45.2
+ B6 congenic mice.
Spleens were harvested from recipient mice at the indicated time
points (Fig 5: plots iii,iv,v,vi) and stained for donor CD45.1
+ SP
P14-CD8
+ thymocytes producing TNF upon in vitro TCR
stimulation. The proportion of donor CD45.1
+ SP P14-CD8
+
thymocytes producing TNF upon TCR stimulation increased over
the time of the experiment (boxed quadrants in Fig 5: plots
iii,iv,v,vi). The donor CD45.1
+ SP P14-CD8
+ thymocytes capable
of TNF production also exhibited an increasing maturation
phenotype (down-regulation of CD24 and up-regulation of
CD45RB and Qa2) that approached a level similar to that of
splenic T cells by day 14 after transfer. While the recovery of
donor cells diminished over time, as shown in Table 1, we also
observed increases in the mean fluorescence intensity (MFI) of the
TNF signal in naı ¨ve (CD44
lo) donor CD45.1
+ SP P14-CD8
+
thymocytes producing TNF from day 2 to day 14 after transfer
(Table 1). This increase in expression of TNF on a per cell basis by
donor SP CD45.1
+ P14-CD8
+ thymocytes was significant
(p,0.05) and was consistent with the increasing maturation
phenotype observed at these time points (Fig 5 and Table 2). We
next compared the changes in MFI of maturation markers in the
TNF-producing and non-producing donor thymocytes at day 1
and 2 after transfer, as the TNF
negative populations were very
small at later time points (Table 2). The TNF-producing cells were
more mature, again suggesting that the changes in the maturation
state of donor thymocytes correlated with increasing capability to
produce TNF efficiently on a per cell basis. Pre-transfer
stimulation of thymocytes ex vivo in the presence of CD45.2
+
B6 splenocytes did not affect their maturation status. Together,
these results suggest that the progressive maturation of transferred
SP P14-CD8
+ thymocytes in the periphery positively influences
their capability to competently produce TNF upon TCR
stimulation.
Post-thymic maturation of naturally emigrating
polyclonal SP thymocytes licenses them to produce TNF
efficiently in the periphery
Polyclonal naı ¨ve CD4
+ and CD8
+ T lymphocytes (CD44
lo) from
secondary lymphoid organs rapidly produce TNF after TCR
engagement before gaining other effector functions [8]. However,
it is not known if polyclonal SP thymocytes also lack the capability
to produce TNF like their transgenic counterparts. To determine
this, thymocytes and splenocytes from naı ¨ve non-transgenic B6
mice were stimulated using both monoclonal aCD3 and aCD28
antibodies for 4 hrs in vitro, respectively. Fig. 6A shows that,
similarly to the transgenic T cells, a lower proportion of polyclonal
CD4
+ CD8
2 and CD4
2 CD8
+ SP thymocytes produced TNF
when compared to naı ¨ve (CD44
lo) splenic T cells during TCR
stimulation (Fig 6A). This inability to produce TNF was not
overcome by increasing the concentrations of the peptide or aCD3
(data not shown). Given this difference and the ability of transgenic
SP thymocytes to gradually gain the capability to produce TNF
with time in the periphery (shown in Fig 5), we wanted to directly
test the ability of polyclonal RTEs that are naturally seeding into
the periphery for their ability to produce TNF upon stimulation.
For this, we used mice expressing GFP under the control of the
Rag2 promoter (NG-BAC transgenic mice). The level of GFP
expression by T cells in the periphery of these mice can be used to
identify T cells at different stages of post-thymic maturation. GFP
hi
T cells have resided in the periphery for 0–7 days, GFP
lo T cells
have resided in the periphery for 7–14 days and GFP
neg T cells
have joined the MN T cell pool (.14 days in the periphery) [3].
We compared three T cell subsets: SP thymocytes (GFP
hi), RTEs
(GFP
hi+lo) in the spleen, and MN T cells (GFP
neg) in the spleen
(Fig.6B). A higher proportion of CD8
+ and CD4
+ RTEs produced
TNF in response to aCD3 and aCD28 stimulation when
compared to SP thymocytes (Fig.6B). However, the proportion
of CD8
+ RTEs producing TNF was lower than MN CD8
+ T cell
populations (Fig.6B). This hierarchical pattern of TNF production
was also observed on a per cell basis in the three T cell subsets
(Fig.6C). In contrast to the CD8
+ T cell compartment, a similar
frequency of CD4
+ RTE and MN T cells produced TNF, but the
MFI of the TNF signal was significantly higher in the CD4
+ MN T
cells relative to both CD4
+ RTEs and SP CD4
+ thymocytes
(Fig. 6B and 6C). Together these results support our data from the
adoptive transfer model indicating that post-thymic maturation
confers the complete licensing of naı ¨ve T cells to rapidly produce
TNF after TCR engagement.
Discussion
TNF is the earliest known cytokine produced by naı ¨ve T cells in
secondary lymphoid organs after TCR stimulation [8]. Here, we
show that the unique capability of naı ¨ve T cells to produce TNF is
only acquired via a gradual licensing process that is initiated in the
thymus but is completed progressively in the periphery. Our data
show that SP thymocytes are functionally less competent to
produce TNF upon TCR stimulation relative to naı ¨ve T cells in
the secondary lymphoid organs. This reduced capability for TNF
production is evident at the transcriptional level in SP thymocytes
relative to naı ¨ve splenic T cells during TCR stimulation. Despite
this functional difference, SP thymocytes did not possess any
apparent phenotypic defects when compared to naı ¨ve splenic T
cells during activation (upregulation of CD25 and CD69 and
down-regulation of CD62L). The poor ability of SP thymocytes to
produce TNF was not overcome upon receiving optimal signals
from APCs of secondary lymphoid organs (spleen and lymph
node) during TCR activation, suggesting that SP thymocytes
Figure 2. Reduced upregulation of TNF message in SP thymocytes relative to naı ¨ve splenic T cells upon TCR stimulation. SP P14-CD8
+
thymocytes and (CD44
lo) naı ¨ve splenic CD8
+ T cells were purified by cell sorting and stimulated in the presence of GP33 and GP33+aCD28 for 4 hours
followed by RNA isolation and cDNA synthesis from 50 ng of RNA and then amplified using TNF specific primers by quantitative real time PCR from
the indicated populations as described in Materials and Methods. A, The basal steady state level of TNF transcripts in 50 ng of total RNA (normalized
to a b-actin control) isolated from unstimulated SP P14-CD8
+ thymocytes and (CD44
lo) naı ¨ve splenic T cells are shown. B, The increase in TNF message
in these subsets upon stimulation with GP33 and GP33+aCD28 in terms of fold induction with respect to unstimulated SP thymocytes been
(normalized to a b-actin control) are shown. This profile is representative of 3 individual experiments.
doi:10.1371/journal.pone.0015038.g002
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efficiently upon stimulation. SP thymocytes eventually gain full
competence to produce TNF upon TCR stimulation as they
undergo post-thymic maturation in the periphery and join the
mature-naı ¨ve T cell pool in secondary lymphoid organs and this
licensing for TNF production does not require homeostatic cell
division (data not shown).
Several studies have shown that TNF is expressed in the thymus
and have demonstrated that this TNF has a physiological role
within the thymus. In situ hybridization studies revealed the
localization of TNF mRNA to the cortical regions of the thymus
during ontogeny, and studies by Giroir et.al showed that there was
constitutive expression of TNF in thymic lymphocytes [52,53]. In
vitro functional studies showed that TNF induced CD25
expression in developing (CD117
+ CD25
2) thymocytes in vitro
[54]. TNF also induced apoptosis of CD4
2 CD8
2 double negative
thymocytes that coexpressed both TNFR1 and TNFR2 at low
doses but stimulated proliferation at higher doses [55]. Interest-
ingly, TNFR1/2 double KO mice exhibited thymic hypertrophy
with an overall increase in total thymocytes but had a normal
distribution of SP CD4
+ and SP CD8
+ T cell subsets due to
absence of apoptosis in DN thymocytes [55]. Collectively, the dual
role of TNF in the thymus appears paradoxical and may depend
on the location and the quantity of its production at various stages
of development.
Alternatively, there is also evidence showing the dangerous
effects of deregulated production of TNF in the thymus. For
instance, mice that over-express human TNF within the thymus
exhibit thymic atrophy, which is primarily associated with
premature apoptosis of double negative (DN2) developing
thymocytes and diminished numbers of cortical thymic epithelial
cells (cTECs) [56]. Mice infected with Trypanosoma Cruzi show
severe thymocyte depletion of CD4
+ CD8
+ DP thymocytes due to
an exacerbated inflammatory reaction mediated by TNF [57].
Increased levels of TNF and IFN-c message have been associated
with increased thymocyte deletion and cortical depletion observed
in the thymi of patients with Down-Syndrome (DS) [58,59]. It is
proposed that this abnormality may be due to improper
interactions between developing thymocytes and thymic stromal
cells mediated by elevated levels of LFA-1 and ICAM-1 and an
abnormal distribution of ICAM-1 in DS thymi that is then
exacerbated by the expression of TNF and IFN-c in DS thymi
[60]. These reports suggest that overproduction of TNF in the
thymus may be detrimental to the T cell developmental process.
We detected that resting unstimulated SP thymocytes expressed a
small level of mature TNF message similar to their splenic
counterparts. However, there was no spontaneous production of
TNF protein detected in these cells. This suggests that despite
having a similar basal level of TNF transcription, there is a lack of
translation of the TNF protein under resting conditions in both
these subsets. Therefore, the reduced ability of SP thymocytes to
rapidly produce TNF during TCR engagement in the thymus
under normal circumstances may be beneficial for the survival of
SP thymocytes during T cell selection.
A previous report revealed that TNF production by T cells does
not require de novo mRNA expression from the TNF locus, as
primary CD4 T cells contain a premature TNF transcript which,
following TCR engagement, is spliced to form a mature TNF
message, resulting in the synthesis of TNF protein in the absence
of new transcription [61]. However, we have previously observed
that treatment of naı ¨ve CD8
+ T cells with the transcriptional
inhibitor actinomycin-D completely abrogated the production of
TNF, suggesting that transcription is vital for TNF protein
synthesis by naı ¨ve CD8
+ T cells [8]. Our results here show that
there is a slight but significant upregulation of TNF message in the
CD8
+ SP thymocytes upon TCR stimulation, but this is
insufficient for the optimal production of protein. The splenic T
cells, on the other hand, show a dramatic upregulation in TNF
message and protein upon activation. Work done in Jurkat T cells
and macrophages has revealed that the AU rich regions of the
39UTR of TNF mRNA is vital for TNF regulation [62]. These
findings suggest that there may either be a distinct transcriptional
or post-transcriptional control of TNF gene expression in SP
thymocytes relative to splenic T cells
Stimulation in the presence of splenocytes partially enabled SP
thymocytes to produce TNF efficiently as there was only a partial
increase in the proportion of cells producing the cytokine. This
effect may be either due to better antigen presentation of
exogenous peptides by splenocytes to SP thymocytes. For example,
secondary lymphoid cells (spleen and lymph nodes) might offer
additional accessory signals leading to enhanced clustering of
adhesion molecules during immunological synapse formation and
to the partial production of TNF [63,64]. The alternative
possibility is that there are more antigen presenting cells in the
splenic environment that increase the strength of TCR-MHC
interactions making SP thymocytes more sensitive to stimulation.
We are currently exploring these possibilities. Moreover, this effect
occurs regardless of whether SP thymocytes are stimulated in the
presence of live or killed (c-irradiated) splenocytes, suggesting that
the peptide-MHC complexes and other potential molecules
present on the surface of splenocytes are sufficient for this process.
Nonetheless, thymocytes are still incapable of producing produc-
ing TNF efficiently despite receiving optimal antigen presentation
in the splenic environment.
Contact with secondary lymphoid organs is vital for the
completion of post-thymic maturation of developing SP thymo-
cytes [1]. RTEs that reach the periphery undergo phenotypic and
functional maturation as they become resident in secondary
lymphoid organs [3,65]. Our findings indicate that the full
competence for TNF production by naı ¨ve T cells in the peripheral
T cell pool is acquired gradually in a post-thymic maturation
dependent manner. One caveat for the adoptive transfer model is
that the recovery of thymocytes from the spleens of the recipient
mice decreased over time. Therefore, we cannot exclude the
possibility that the increase in the percentage of TNF producing
donor CD45.1
+ SP P14-CD8
+ thymocytes with time in the
periphery may be due to preferential survival of SP thymocytes
that are capable of TNF production. Nevertheless, the hierarchical
Figure 3. SP thymocytes and splenic T cells exhibit a differential ability to produce TNF during in vivo TCR activation. A and B,
CD45.1
+ P14-CD8
+ and SMARTA-CD4
+ splenocytes were mixed at 1:1 ratio, treated with bfA and transferred into CD45.2
+ congenic hosts that were
uninfected or infected with either WT LCMV Armstrong or the LCMV variant GP1V. CD45.1
+ P14-CD8
+ and SMARTA-CD4
+ thymocytes were treated
with bfA and transferred separately into CD45.2
+ congenic hosts that were infected with either WT LCMV Armstrong or the viral variant GP1V. Spleens
from all recipient mice were harvested 4 hours later and directly stained for intracellular TNF. The percentages of donor CD45.1
+ P14-CD8
+ and
SMARTA-CD4
+ splenic T cells and SP thymocytes that are TNF positive and have down-regulated CD62L are shown. C, The average percentages of
CD62L
loTNF
+ donor T cells detected ex vivo are shown. One-way ANOVA with Tukey post-test was used to compare the mice that received P14
thymocytes or splenocytes and were either uninfected or infected with WT LCMV strain or the viral mutant strain (p,0.05). These data are a pool of 6
experiments. Error bars indicate SD.
doi:10.1371/journal.pone.0015038.g003
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e15038Figure 4. TNF producing SP thymocytes exhibit a lower maturation profile relative to their splenic counterparts. A and B, CD45.1
+
P14-CD8
+ thymocytes were stimulated with GP33+aCD28 for 4 hours in vitro and then stained for maturation markers and intracellular TNF, as
described in Materials and Methods. The TNF producers and non producers of the thymic and the splenic subsets were each classified into 4
subgroups based on their CD24 and Qa2 expression as shown namely Subgroup 1 (CD24
hi Qa2
lo) followed by Subgroup 2 (CD24
hi-int Qa2
lo),
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thymocytes and polyclonal RTEs clearly indicates that the
progressive gain in the TNF producing capability of naı ¨ve T cells
occurs as they mature in the periphery.
In mice, developing thymocytes emigrate and populate the
periphery at the rate of 1–2% of thymocytes per day throughout
the life [66,67]. Therefore, at any given time in an adult immune
system, the naı ¨ve T cell pool is comprised of cells at various stages
of post-thymic development, unlike neonates whose peripheral
lymphoid organs are predominantly populated with RTEs [2,65].
The post-thymic maturation status of T cells is a component that
has been recently shown to influence T cell fate decisions at the
time of antigen encounter [2]. This study showed that RTEs
produced fewer memory-precursor effector cells (MPECs) and
more short-lived effector cells (SLECS) during the immune
response to LCMV. Our data show that RTEs produce less
TNF relative to MN T cells. Given the immunoregulatory
functions of TNF, we speculate that the differential ability of
TNF production linked to the post-thymic maturation status of
antigen-specific naı ¨ve T cells, may also contribute to influencing
the fate of the responding T cells during the initial phase of
activation.
In conclusion, our findings indicate that the licensing of naı ¨ve T
cells for rapid TNF production is determined by their develop-
mental state. It is an intrinsic property of the developing T cells
that is acquired gradually, where functional maturation in
secondary lymphoid organs drives developing naı ¨ve T cells to
eventually attain full competence to produce TNF efficiently
during TCR stimulation.
Materials and Methods
Ethics Statement
All the experiments with animals were done in compliance with
the institutional guidelines as approved by the University of
Massachusetts Institutional Animal Care and Use Committee
(IACUC). Animals were maintained in accordance with the Guide
for the Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, 1996).
Mice
Male and female CD45.2
+ C57BL/6J (B6) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME) and used at 6–12
weeks of age. CD45.1
+ P14 CD8
+ TCR-transgenic mice, with T
cells that recognize the D
b-restricted, LCMV epitope GP33-41
[68,69], and CD45.1
+ SMARTA CD4
+ TCR-transgenic mice,
with T cells that recognize the IA
b-restricted, LCMV epitope
GP61-80 [70], were bred at the University of Massachusetts
Medical School (UMMS) Department of Animal Medicine.
CD45.1
+ OT-1 CD8 TCR-transgenic mice, with T cells that
recognize the K
b-restricted, ovalbumin epitope OVA257-264
[71], and CD45.1
+ OT-2 CD4 TCR-transgenic mice, with T cells
that recognize the IA
b-restricted, ovalbumin epitope OVA323-339
[72] were provided by Dr. Kenneth Rock (Department of
Pathology, UMMS, Worcester, MA). NG-BAC transgenic mice,
originally obtained from Dr. Michel Nussenzweig were back-
crossed to the CD45.1
+ and CD45.2
+ background and were used
at 6–12 weeks of age [3,73]. Homozygous C57BL/6Ji-D
btm1 N12
(H-2D
b KO) mice were purchased from Taconic Farms and used
at 6 weeks of age. All animals were housed and maintained within
the Department of Animal Medicine at UMMS.
Viruses
Stocks of LCMV, strain Armstrong, and a LCMV variant
GP1V virus that possesses an amino acid mutation at position 38
(F to L) in the GP33-41 epitope of LCMV Armstrong were used.
This mutation results in the escape of the virus from recognition by
LCMV specific D
b-restricted CTL [74]. Both LCMV stocks were
prepared in baby hamster kidney cells (BHK21), as previously
described, and mice were infected with 5610
4 PFU of each virus
strain i.p. [8].
Flow cytometry and intracellular cytokine assays
Single cell suspensions of thymocytes and splenocytes were
prepared in RPMI 1640 supplemented with 10% FBS, 100U/ml
penicillin, 100mg/ml streptomycin sulfate and 2mM L-glutamine
and stimulated as indicated. For intracellular cytokine assays,
lymphocytes (2610
6 cells) were stimulated with either 1 mM of the
indicated peptide with monoclonal antibodies specific for CD3e
(0.25 mg/ml, 145-2C11, BD Pharmingen) and CD28 (2.5mg/ml,
37.51, BD Pharmingen) or with PMA (0.5 mg/ml) and ionomycin
(0.5mg/ml) in the presence of GolgiPlug
TM (0.1 mg/ml) for 4 hours
at 37uCi n5 %C O 2. In some experiments, thymocytes were co-
cultured at 1:1 ratios with either splenocytes from the indicated
mouse strains or with the indicated cell populations derived from
the spleens of congenic B6 mice and stimulated simultaneously.
After the incubation, cells were stained with monoclonal
antibodies specific for congenic markers (CD45.1: A20) and
(CD45.2: 104), CD4 (RM4-5), CD8 (53-6.7), CD25 (PC61), CD44
(IM7), CD62L (MEL-14), CD69 (H1.2F3), CD24 (M1/69), Qa2
(1-1-2), TCR Va2 mAb (B20.1) and Vb8.1 mAb (MR5-2)
purchased from BD Pharmingen and CD45RB (C363.16A) from
eBioscience. Following the surface stain, cells were fixed and
permeabilized using BD Cytofix/Cytoperm
TM solution and then
stained for intracellular TNF (MP6-XT22 from BD Pharmingen)
and CD4 as described previously [8]. For analysis of lymphocytes
from NG-BAC transgenic mice, GFP positive cells were
determined on the basis of the fluorescence intensity found in
SP thymocytes [3]. Fixation slightly diminished the GFP signal
during intracellular staining but lymphocytes could still be
differentiated as GFP
hi+lo and GFP
neg cells in the thymus and
the spleen. Samples were analyzed using a Becton Dickinson
LSRII Flow Cytometer (BD Biosciences) and FlowJo software
(Tree star Inc, Ashland, OR).
Cell purification and enrichment
Single cell suspensions of thymocytes and splenocytes from P14
TCR transgenic mice were purified by staining with anti-CD4,
anti-CD8 and anti-CD44 antibodies in 16 PBS with 2% FBS,
2mM EDTA and sorted for CD4
2 CD8
+ SP thymocytes and
naı ¨ve (CD44
low) splenic T cells using the MoFlo
TM XDP cell sorter
(Beckton Coulter). The purity of SP CD8 thymocytes was 98%
Subgroup 3 (CD24
lo Qa2
lo) and finally Subgroup 4 (CD24
lo Qa2
hi). C, shows the histogram comparison of the small population of TNF producing SP
thymocytes (dotted line histograms), the majority of SP thymocytes that are TNF non-producers (gray histograms) and TNF producing splenic T cells
(solid dark line histograms) and TNF non-producing splenic T cells (black histograms). The MFIs of each of the maturation markers in TNF producing
and non-producing thymic and splenic T cells are indicated in the left hand side of the histograms respectively. D, shows the maturation profile of the
total SP CD8
+ thymocytes based on their CD24 and Qa2 expression. The proportion of cells capable of making TNF in the 4 subgroups is shown with
respect to CD45RB expression.
doi:10.1371/journal.pone.0015038.g004
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e15038Figure 5. Post-thymic maturation status of naı ¨ve P14 transgenic T cells determines their TNF producing capability. Female CD45.1
+
P14-CD8
+ thymocytes were transferred into female CD45.2
+ B6 congenic mice. Host spleens were recovered after the indicated time periods and
were stimulated in vitro for 4 hours with GP33+aCD28 and donor CD45.1
+ T cells were stained for intracellular TNF as described in Materials and
Methods. Dead cells were excluded using Live Dead Aqua Dead cell stain for this experiment. For analysis, cells were gated on the live donor SP P14-
CD8
+ T cells and the maturation profile of donor cells that are TNF
+ (indicated by arrows in the boxed quadrants in plots iii,iv,v,vi) were compared at
all the time points shown (corresponding histograms). Additionally, some CD45.1
+ P14-CD8
+ thymocytes were stimulated before transfer in the
context of CD45.2
+ B6 splenocytes in vitro for 4 hours with GP33+aCD28 and their maturation profile was compared to CD45.1
+ P14-CD8
+
thymocytes and splenocytes stimulated alone in vitro (plots i, ii and vii).
doi:10.1371/journal.pone.0015038.g005
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+CD44
low splenic T cells was 90.3%. For
cell enrichment, subsets of P14-CD8
+ T cells were obtained by
negative magnetic selection in 16 PBS with 2% FBS, 2mM
EDTA. For this, thymocytes were depleted of CD4
+ cells and
splenocytes were depleted of CD4
+ and CD19
+ cells by initially
staining the cells with biotinylated anti-CD4 (RM4-5; BD
Pharmingen) and anti-CD19 (ID3; BD Pharmingen) followed by
selection with Streptavidin (SA) microbeads (Miltenyi Biotech,
Auburn, CA). The purification of CD8
+ cells after negative
selection was 60% from both tissues. To isolate cell subsets from
the CD45.2
+ splenocytes for the co-culture experiments described
above, B cells were positively selected using anti-CD19 microbeads
and T cells were positively selected by Thy1.2 microbeads
(Miltenyi Biotech). The cells remaining in the flow-through were
used as a source of splenic APCs (20% CD11c
+).
Real-time PCR
T cell subsets purified either by sorting or enrichment were used
as indicated. Total RNA was isolated using a RNA isolation kit
(Qiagen Valencia, CA). An additional step was incorporated to
remove genomic DNA using a RNAse-free DNAse kit (Qiagen).
The concentration of recovered RNA was determined using the
NanoDropH ND-1000 spectrophotometer (Thermo Scientific
Willmington, DE). RNA (25 or 50 ng as indicated) was reverse-
transcribed into cDNA using Superscript
TM III first strand
synthesis system (Invitrogen Carlsbad,CA) using oligo(dT) prim-
ers. Amplification of the cDNA was then performed by Real time
PCR with the SYBRH green mastermix (Applied Biosystems
Foster City, CA) using MyiQ
TM BioRad icycler. The following
TNF primers: FW 59-CAT CTT CTC AAA ATT CGA GTG
ACA A-39,R V5 9- TGG GAG TAG ACA AGG TAC AAC CC-
39 primers (annealing temp: 60uC and 175 bp product) [75]; b
actin primers: FW 59-CGA GGC CCA GAG CAA GAG AG-39,
RV 59- CGG TTGGCC TTA GGGTTC AG-39 and (annealing
temp: 62uC and 150 bp product) were used. The following
program was used for the real time PCR reaction, Cycle 1: (16)
step 1: 95uC for 10:00; Cycle 2: (406)s t e p1 :9 5 uC for 00:15; step
2: 60uC for 1:00; Cycle 3: (16)s t e p1 :9 5uC for 1:00; Cycle 4: (806)
Step 1: 55uC for 00:10. For absolute quantification of the data,
standard curves were generated using serial dilution of pCRH 4–
TOPO M13 plasmids containing cDNA clones of TNF and b
actin.
Table 1. SP thymocytes acquire the ability to produce TNF as a function of time in the periphery
a.
Group Days post-transfer Absolute number of donor P14-CD8
+ T cells (610
4) TNF MFI of TNF
+CD44
lo donor T cells (610
2)
1. Day 1 48682 4 64
2. Day 2 36618 2462
3. Day 7 14610
b 4764
d,f
4. Day 14 562
c 64619
e,g,h
aThe recovery of the donor (CD44
lo) SP P14-CD8
+ thymocytes from recipient spleens and the MFI of TNF expression at the indicated time points post-transfer are shown.
The average recovery and the MFI of TNF expression by donor thymocytes (n=6 per time point) were analysed using One-way ANOVA with a Tukey post-test as
described in Materials and Methods. Error indicates SD. N/A, Not Applicable.
bp,0.05 vs Table 1, group 1.
cp,0.05 vs Table 1, group 1.
dp,0.05 vs Table 1, group 1.
ep,0.05 vs Table 1, group 1.
fp,0.05 vs Table 1, group 2.
gp,0.05 vs Table 1, group 2.
hp,0.05 vs Table 1, group 3.
doi:10.1371/journal.pone.0015038.t001
Table 2. Maturation state of SP thymocytes reflects their TNF producing capability
a.
Group Days post-transfer CD24 MFI of donor T cells (610
2) CD45RB MFI of donor T cells (610
2) Qa2 MFI of donor T cells (610
2)
TNF+ TNF2 TNF+ TNF2 TNF+ TNF2
1. Day1 24663 4 67
h 239615 137614
j 1.460.1 0.160.1
2. Day2 20633 1 65
i 305633
d 244637 4.962.2 2.860.8
3. Day7 1563
b N/A 588626
e N/A 7.460.8 N/A
4. Day14 1362
c N/A 629627
f N/A 11.565.6
g N/A
aThe average MFI of maturation markers CD24 (n=6), CD45RB (n=6) and Qa2 (n=3 for group1 and 2 and n=6 for for group 3 and 4) in TNF producing donor SP P14-
CD8
+ are shown. The averages were analysed using One-way ANOVA with a Tukey post-test as described in Materials and Methods. Error indicates SD. N/A, Not
Applicable.
bp,0.05 vs Table II, group 1.
cp,0.05 vs Table II, group 1.
dp,0.05 vs Table II, group 1.
ep,0.05 vs Table II, group 1.
fp,0.05 vs Table II, group 1.
gp,0.05 vs Table II, group 1.
hp,0.05 vs Table II, group 1 TNF+.
ip,0.05 vs Table II, group 1 TNF+.
jp,0.05 vs Table II, group 1 TNF+.
doi:10.1371/journal.pone.0015038.t002
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PLoS ONE | www.plosone.org 12 November 2010 | Volume 5 | Issue 11 | e15038Figure 6. Post-thymic maturation status of naı ¨ve polyclonal T cells determines their TNF producing capability. A, The percentages of
non-transgenic CD8
+ and CD4
+ cells (both CD44
lo and CD44
hi) from thymi and spleens of B6 mice staining positive for TNF cytokine are shown. B,
Thymocytes and splenocytes from NG-BAC transgenic mice were stimulated with aCD3+aCD28 for 4 hours and then stained for maturation markers
and intracellular TNF. The GFP profile of SP thymocytes, RTEs and MN T cells in the CD8
+ and CD4
+ compartments is shown. B and C, The percentages
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This assay was modified from a previously published protocol
[45] and used to detect TCR-transgenic T cells producing TNF in
vivo. Briefly, unpurified thymocytes or splenocytes from CD45.1
+
P14 and CD45.1
+ SMARTA mice 10610
6 each (mixed at a 1:1
ratio) were treated in vitro with 0.5 mg/ml GolgiPlug (BD
biosciences) for 20 min at 37uC. Following the incubation, the
cells were adoptively transferred into CD45.2
+ B6 hosts that were
infected 2 days previously with 5610
4 PFU of LCMV Armstrong
or GP1V CTL escape variant. Additionally each mouse received
250 mg of bfA (Sigma) i.v. Four hours after transfer, host spleens
were harvested and donor T cells were stained directly for TNF
using the intracellular cytokine staining protocol as described
above. Additionally, 20610
6 P14 thymocytes and splenocytes were
transferred separately into uninfected CD45.2
+ B6 hosts in the
absence of bfA. Host spleens were harvested 1, 2, 7 and 14 days
after transfer and stimulated in vitro with 1 mM GP33 peptide and
aCD28 (2.5mg/ml) in the presence of GolgiPlug
TM (0.1 mg/ml) for
4 hours at 37uCi n5 %C O 2 followed by standard intracellular
cytokine staining protocol for TNF by donor T cells as described
above. Dead cells were excluded using Live Dead Aqua Dead cell
stain (Invitrogen; Molecular probes Carlsbad, CA) for this
experiment.
Statistics
Sample analyses were done using Graph Pad Prism (Graph Pad
Software). A one-way ANOVA with a Tukey post-test was used to
compare multiple samples, with a P value of ,0.05 considered
significant.
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